Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial.

John H SampsonAchal Singh AchrolManish K AghiKrystof BankiewieczMartin BexonSteven BremAndrew BrennerChandtip ChandhasinSajeel ChowdharyMelissa CoelloBenjamin M EllingsonJohn R FloydSeunggu HanSantosh KesariYael MardorFahar MerchantNina MerchantDina RandazzoMichael VogelbaumFrank VrionisEva Wembacher-SchroederMiroslaw ZabekNicholas Butowski

Published in: Neuro-oncology (2023)

MDNA55 demonstrated tumor control and promising survival and may benefit rGBM patients when treated at high dose irrespective of IL4R expression level.

Keyphrases

high dose
end stage renal disease
newly diagnosed
peritoneal dialysis
low dose
clinical trial
prognostic factors
binding protein
study protocol
free survival